
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical is positioned to revolutionize the minimally invasive surgery space with its LIBERTY Endovascular Robotic Surgical System, the only FDA-cleared, single-use, remotely operated robotic system. Its limited market release phase was successful, with rapid customer adoption and shorter sales cycles, and its full market release at the SIR annual scientific meeting this week is expected to drive significant sales ramp-up in the remainder of 2026. Additionally, with a strong IP portfolio, global patent approvals, and a focused go-to-market strategy targeting key procedures and facilities, the company is well-positioned for success.
Bears say
Microbot Medical is a company with limited current sales but high expectations for future growth with its LIBERTY Endovascular Robotic System. However, there are several potential risks that could impede its success, including forecasting, competitive, regulatory, and manufacturing risks. Additionally, the company's current cash balance may not be sufficient to reach profitability in the near term, and its dependence on a single product could also pose a concentration risk.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares